Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19

Background Venous thromboembolism (VTE) contributes significantly to COVID‐19 morbidity and mortality. The urokinase receptor system is involved in the regulation of coagulation. Levels of soluble urokinase plasminogen activator receptor (suPAR) reflect hyperinflammation and are strongly predictive...

Full description

Bibliographic Details
Main Authors: Shengyuan Luo, Alexi Vasbinder, Jeanne M. Du‐Fay‐de‐Lavallaz, Joanne Michelle D. Gomez, Tisha Suboc, Elizabeth Anderson, Annika Tekumulla, Husam Shadid, Hanna Berlin, Michael Pan, Tariq U. Azam, Ibrahim Khaleel, Kishan Padalia, Chelsea Meloche, Patrick O'Hayer, Tonimarie Catalan, Pennelope Blakely, Christopher Launius, Kingsley‐Michael Amadi, Rodica Pop‐Busui, Sven H. Loosen, Athanasios Chalkias, Frank Tacke, Evangelos J. Giamarellos‐Bourboulis, Izzet Altintas, Jesper Eugen‐Olsen, Kim A. Williams, Annabelle Santos Volgman, Jochen Reiser, Salim S. Hayek
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
COVID‐19
soluble urokinase plasminogen activator receptor
thromboembolism
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.122.025198

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.122.025198

Similar Items